Healthcare / BiotechnologyShenzhen
$15.77
-0.42 (-2.59%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-71.2M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
38/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.2B
P/E
46.4x
↑EV/EBITDA
29.4x
↑ROE
5.1%
↑Gross Margin
51.5%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-0.3%
FCF CAGR
—
FCF margin
-47.2%
FCF / Net income
-1.83x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $365.9M · net income $94.5M · FCF $-172.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $365.9M | $365.9M | $302.8M | $299.2M | $369.2M |
| Net Income | $94.5M | $94.5M | $94.4M | $93.5M | $109.9M |
| EBITDA | $137.7M | $137.7M | $135.2M | $122.9M | $144.1M |
| EPS | 0.36 | 0.36 | 0.36 | 0.35 | 0.49 |
| Gross Margin | 51.5% | 51.5% | 58.3% | 54.6% | 52.0% |
| Operating Margin | 23.1% | 23.1% | 25.0% | 24.6% | 31.4% |
| Net Margin | 25.8% | 25.8% | 31.2% | 31.2% | 29.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Current Ratio | 7.73 | 7.73 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-172.7M | $-172.7M | $-69.4M | $-71.2M | $64.3M |
| Returns | |||||
| ROE | 5.1% | 5.1% | 5.3% | 5.4% | 6.5% |
| Valuation | |||||
| P/E | 46.38 | 46.38 | 37.75 | 52.29 | 46.12 |
| EV/EBITDA | 29.37 | 29.37 | 25.56 | 38.31 | 29.15 |
| P/B | 2.25 | 2.25 | 1.99 | 2.82 | 2.99 |
| Growth & Yield | |||||
| Revenue Growth | 20.8% | 20.8% | 1.2% | -18.9% | — |
| EPS Growth | 0.0% | 0.0% | 2.9% | -28.6% | — |
| Dividend Yield | 0.9% | 0.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
57.2%
EPS terminal req.
$1.40
Spread vs growth
-57.2%
5Y implied EPS CAGR
36.3%
EPS terminal req.
$1.69
Spread vs growth
-36.3%
10Y implied EPS CAGR
22.4%
EPS terminal req.
$2.73
Spread vs growth
-22.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+6.2%
Start / end P/E
41.6x → 43.8x
EPS bridge
0.36 → 0.36
Residual
-0.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.